Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Colorcon
McKinsey
Moodys
Baxter

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)

See Plans and Pricing

« Back to Dashboard

Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-05-02
Court District Court, D. Delaware Date Terminated 2009-01-07
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties AVENTIS PHARMACEUTICALS INC.; BARR LABORATORIES INC.; SANOFI-AVENTIS US LLC
Patents 10,086,011; 10,124,014; 10,184,001; 3,897,779; 4,018,895; 4,335,121; 4,405,598; 4,587,258; 4,590,213; 4,767,612; 4,782,047; 4,837,223; 4,843,086; 4,886,812; 4,933,168; 4,943,639; 4,971,998; 4,983,595; 5,053,407; 5,061,722; 5,216,007; 5,439,670; 5,461,081; 5,540,930; 5,543,434; 5,976,573; 6,121,021; 6,143,329; 6,673,337; 7,012,066; 7,449,012; 9,194,011
Attorneys John G. Day; Josy W. Ingersoll; Karen Elizabeth Keller; Karen L. Pascale; Steven J. Balick; Tiffany Geyer Lydon
Firms Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Biologic Drugs cited in Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc.

Details for Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2006-05-02 1 Complaint cavities, U.S. Pat. Nos. 3,780, 176; 3,809,294; 3,897,779; 4,405,598; 4,250,163; 4,294, 829; 4,304,765; ….... 154/39 3,809,294 5/1974 Torgeson 222/182 3,897,779 8/1975 Hansen .......... 128/203.15 4,226,848 …cavities, U.S. Pat. Nos 3,780,176; 3,809,294; 3,897,779; 4,405,598; 4,250,163; 4,294,829; 4,304,765; 4,407,792…and 1400(b). The Patents 8. United States Patent No. 5,976,573 (“the ‘57 3 patent”) duly and legally…Action 4. This is an action for patent infringement arising under the patent laws of the United States, Title External link to document
2006-05-31 10 Opening Brief in Support __._S_., Patent Nos. 4.837.223 (the “ "223 natent”1 and 4.943.639 (the “ '639 patent") for…has infringed two patents Aventis owns, U.S. Patent Nos. 5,976,573 (“the ‘573 patent”) and 6,143,329 (…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent 35 U.S.C…inventors 3 patent case that we have. patent cases by definition are 4 on one of the patents at the time… the Patent Act permits an award of enhanced damages for willful infringement in ordinary patent infringement External link to document
2006-06-09 11 Answer to Counterclaim Sanofi-Aventis listed U.S. Patent Nos. 5,976,573 ("the '573 patent") and 6,143,329 ("…and '329 patents, Barr's ANDA includes paragraph IV certifications to those patents. ANSWER… include, among other things, the number of any patent that claims the "drug" or a "method… the NDA was submitted and for which a claim of patent infringement could reasonably be asserted against…6. Upon approval of the NDA, FDA publishes patent information for the approved drug in the " External link to document
2007-09-10 116 Claim Construction Opening Brief allegedly disclosed in the patents-in-suit, U.S. Patent Nos. 5,976,573 (the “‘573 patent”) and 6,143,329 (the…329 patent is a continuation of the application from which the ‘573 patent issued. The two patents share… the patent specification and the applicant’s representations to the Patent Office during patent prosecution… 34 Of The ‘573 Patent And Claims 13, 14 And 25 Of The ‘329 Patent Is Limited To The… C. Claim 1 Of The ‘573 Patent And Claim 6 Of The ‘329 Patent Recite Specific External link to document
2007-09-10 117 Claim Construction Opening Brief et al. in view of Weg (U.S. Patent No. 5,543,434) and June (U.S. Patent No. 5,429,824). Id. The inventor…infringement of U.S. Patent Nos. 5,976,573 (“the ‘573 patent”) and 6,143,329 (“the ‘329 patent”) (collectively… except in the patented formulation. B. The ‘573 Patent The ‘573 patent, entitled “Aqueous-based…” A11 (‘573 patent claim 34); A21-A22 (‘329 patent claims 1 and 6); A9-A10 (‘5783 patent claims 1 and…high.” A9 (‘573 patent claim 1); A21 (‘329 patent claim 6). Claim 5 of the ‘573 patent and claim 1 of External link to document
2007-12-06 130 Order claims of U.S. Patent Nos. 5,976,573 (the “‘573 patent”) and 6,143,329 (the “‘329 patent”): 1. The… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 5,976,573 AND 6,143,329. Signed by Judge Gregory M… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 5,976,573 and 6,143,329 After having considered…description and in distinguishing the prior art. See ‘573 Patent, Abstract (“An aqueous pharmaceutical composition… at A211 (record of the teleconference with the patent examiner explaining that the examiner would allow External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.